Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib and Axitinib with Docetaxel in Advanced NSCLC
NCT00386555Phase 2Withdrawn
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- May 2007
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of crenolanib, axitinib in non-small cell lung cancer (NSCLC), sponsored by AROG Pharmaceuticals, Inc.. Planned start May 2007; status: withdrawn.
02
Drugs
crenolanibaxitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00386555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386555.